An interesting and reciprocal association between the metabolic syndrome and prostate cancer has been identified.
Metabolic alterations, such as hyperinsulinemia, increased levels of insulin growth factor-1, and insulin resistance could be on the basis of development and progression of many tumors, including prostate cancer, and changes in body composition, in turn, can represent some side effects of androgen deprivation therapy and novel drugs, such as mammalian target of rapamycin inhibitors. This review evaluates this interrelation between metabolic syndrome and prostate tumor scanning in many clinical and preclinical epidemiological studies and describes possible pathogenetic biological mechanisms. Finally, this article discusses feasible clinical implications for the management, prevention, diagnosis, prognosis, and treatment of patients affected by metabolic syndrome and prostate cancer, with particular attention to the metformin action.
Written by:
Conteduca V, Di Lorenzo G, Bozza G, Ardito R, Aieta M. Are you the author?
Centro di Riferimento Oncologico della Basilicata IRCCS, Rionero in Vulture, Italy.
Reference: Clin Genitourin Cancer. 2013 May 20. pii: S1558-7673(13)00055-4.
doi: 10.1016/j.clgc.2013.04.009
PubMed Abstract
PMID: 23701880
UroToday.com Prostate Cancer Section
